Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Apr;95(4):1490–1496. doi: 10.1172/JCI117820

The effect of cyclic-AMP on the regulation of c-myc expression in T lymphoma cells.

D A Albert 1
PMCID: PMC295631  PMID: 7706453

Abstract

Myc is implicated in the control of growth in a variety of cell types. I investigated c-myc gene expression in several lymphoid cell lines to determine the response to cyclic AMP. Cyclic AMP causes a precipitous decline in c-myc message concentration that precedes G1 cell cycle arrest in wild type S49 cells but not in KIN- cells that lack cAMP dependent PKA activity. In wild-type S49 cells washout of cyclic AMP restores c-myc message levels within 2 h but does not relieve the G1 arrest until 10 h later. Transcription runoff studies demonstrate inhibition of both transcriptional initiation and prolongation of initiated transcripts. However, the degree of inhibition is insufficient to explain the absence of detectable myc message suggesting that the predominant effect of cyclic AMP is to destabilize the c-myc message. In contrast to wild-type cells, the "Deathless" mutant S49 cell line is viable when arrested in G1 by exposure to cyclic AMP and has preserved c-myc expression. Thus, in S49 cells down regulation of c-myc expression appears to be associated with loss of viability rather than G1 cell cycle arrest. Interestingly, CEM human T lymphoma cells do not arrest in G1 phase when exposed to cyclic AMP in spite of losing detectable c-myc gene expression. This suggests that in some T lymphoma cells c-myc gene expression may not be necessary for cell cycle progression and proliferation.

Full text

PDF
1490

Images in this article

1491Image
on p.1491
1491Image
on p.1491
1492Image
on p.1492
1492Image
on p.1492
1493Image
on p.1493
1494Image
on p.1494

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert D. A., Nodzenski E. Ribonucleotide reductase gene expression during cyclic AMP-induced cell cycle arrest in T lymphocytes. Exp Cell Res. 1992 Dec;203(2):476–482. doi: 10.1016/0014-4827(92)90023-2. [DOI] [PubMed] [Google Scholar]
  2. Andersson K. B., Deggerdal A., Skjønsberg C., Smeland E. B., Blomhoff H. K. Constitutive expression of c-myc does not relieve cAMP-mediated growth arrest in human lymphoid Reh cells. J Cell Physiol. 1993 Oct;157(1):61–69. doi: 10.1002/jcp.1041570108. [DOI] [PubMed] [Google Scholar]
  3. Bentley D. L., Groudine M. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature. 1986 Jun 12;321(6071):702–706. doi: 10.1038/321702a0. [DOI] [PubMed] [Google Scholar]
  4. Bissonnette R. P., Echeverri F., Mahboubi A., Green D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 1992 Oct 8;359(6395):552–554. doi: 10.1038/359552a0. [DOI] [PubMed] [Google Scholar]
  5. Blackwood E. M., Eisenman R. N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991 Mar 8;251(4998):1211–1217. doi: 10.1126/science.2006410. [DOI] [PubMed] [Google Scholar]
  6. Cleveland D. W., Yen T. J. Multiple determinants of eukaryotic mRNA stability. New Biol. 1989 Nov;1(2):121–126. [PubMed] [Google Scholar]
  7. Coffino P., Gray J. W., Tomkins G. M. Cyclic AMP, a nonessential regulator of the cell cycle. Proc Natl Acad Sci U S A. 1975 Mar;72(3):878–882. doi: 10.1073/pnas.72.3.878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cole M. D., Mango S. E. cis-acting determinants of c-myc mRNA stability. Enzyme. 1990;44(1-4):167–180. doi: 10.1159/000468755. [DOI] [PubMed] [Google Scholar]
  9. Dani C., Blanchard J. M., Piechaczyk M., El Sabouty S., Marty L., Jeanteur P. Extreme instability of myc mRNA in normal and transformed human cells. Proc Natl Acad Sci U S A. 1984 Nov;81(22):7046–7050. doi: 10.1073/pnas.81.22.7046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dean M., Cleveland J. L., Rapp U. R., Ihle J. N. Role of myc in the abrogation of IL3 dependence of myeloid FDC-P1 cells. Oncogene Res. 1987 Aug;1(3):279–296. [PubMed] [Google Scholar]
  11. Dowd D. R., Miesfeld R. L. Evidence that glucocorticoid- and cyclic AMP-induced apoptotic pathways in lymphocytes share distal events. Mol Cell Biol. 1992 Aug;12(8):3600–3608. doi: 10.1128/mcb.12.8.3600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Duyao M. P., Buckler A. J., Sonenshein G. E. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4727–4731. doi: 10.1073/pnas.87.12.4727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Eastman-Reks S. B., Vedeckis W. V. Glucocorticoid inhibition of c-myc, c-myb, and c-Ki-ras expression in a mouse lymphoma cell line. Cancer Res. 1986 May;46(5):2457–2462. [PubMed] [Google Scholar]
  14. Eick D. Elongation and maturation of c-myc RNA is inhibited by differentiation inducing agents in HL60 cells. Nucleic Acids Res. 1990 Mar 11;18(5):1199–1205. doi: 10.1093/nar/18.5.1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  16. Hay N., Bishop J. M., Levens D. Regulatory elements that modulate expression of human c-myc. Genes Dev. 1987 Sep;1(7):659–671. doi: 10.1101/gad.1.7.659. [DOI] [PubMed] [Google Scholar]
  17. Hay N., Takimoto M., Bishop J. M. A FOS protein is present in a complex that binds a negative regulator of MYC. Genes Dev. 1989 Mar;3(3):293–303. doi: 10.1101/gad.3.3.293. [DOI] [PubMed] [Google Scholar]
  18. Heikkila R., Schwab G., Wickstrom E., Loke S. L., Pluznik D. H., Watt R., Neckers L. M. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. 1987 Jul 30-Aug 5Nature. 328(6129):445–449. doi: 10.1038/328445a0. [DOI] [PubMed] [Google Scholar]
  19. Jücker M., Schaadt M., Diehl V., Poppema S., Jones D., Tesch H. Heterogeneous expression of proto-oncogenes in Hodgkin's disease derived cell lines. Hematol Oncol. 1990 Jul-Aug;8(4):191–204. doi: 10.1002/hon.2900080404. [DOI] [PubMed] [Google Scholar]
  20. Karn J., Watson J. V., Lowe A. D., Green S. M., Vedeckis W. Regulation of cell cycle duration by c-myc levels. Oncogene. 1989 Jun;4(6):773–787. [PubMed] [Google Scholar]
  21. Kato G. J., Lee W. M., Chen L. L., Dang C. V. Max: functional domains and interaction with c-Myc. Genes Dev. 1992 Jan;6(1):81–92. doi: 10.1101/gad.6.1.81. [DOI] [PubMed] [Google Scholar]
  22. Kelly K., Cochran B. H., Stiles C. D., Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983 Dec;35(3 Pt 2):603–610. doi: 10.1016/0092-8674(83)90092-2. [DOI] [PubMed] [Google Scholar]
  23. Lemaire I., Coffino P. Cyclic AMP-induced cytolysis in S49 cells: selection of an unresponsive "deathless" mutant. Cell. 1977 May;11(1):149–155. doi: 10.1016/0092-8674(77)90325-7. [DOI] [PubMed] [Google Scholar]
  24. Maroder M., Martinotti S., Vacca A., Screpanti I., Petrangeli E., Frati L., Gulino A. Post-transcriptional control of c-myc proto-oncogene expression by glucocorticoid hormones in human T lymphoblastic leukemic cells. Nucleic Acids Res. 1990 Mar 11;18(5):1153–1157. doi: 10.1093/nar/18.5.1153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Marzluff W. F., Jr Transcription of RNA in isolated nuclei. Methods Cell Biol. 1978;19:317–332. doi: 10.1016/s0091-679x(08)60032-1. [DOI] [PubMed] [Google Scholar]
  26. Meinkoth J. L., Montminy M. R., Fink J. S., Feramisco J. R. Induction of a cyclic AMP-responsive gene in living cells requires the nuclear factor CREB. Mol Cell Biol. 1991 Mar;11(3):1759–1764. doi: 10.1128/mcb.11.3.1759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Meulia T., Krumm A., Spencer C., Groudine M. Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter. Mol Cell Biol. 1992 Oct;12(10):4590–4600. doi: 10.1128/mcb.12.10.4590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Moberg K. H., Logan T. J., Tyndall W. A., Hall D. J. Three distinct elements within the murine c-myc promoter are required for transcription. Oncogene. 1992 Mar;7(3):411–421. [PubMed] [Google Scholar]
  29. Montminy M. R., Bilezikjian L. M. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature. 1987 Jul 9;328(6126):175–178. doi: 10.1038/328175a0. [DOI] [PubMed] [Google Scholar]
  30. Rabbitts P. H., Watson J. V., Lamond A., Forster A., Stinson M. A., Evan G., Fischer W., Atherton E., Sheppard R., Rabbitts T. H. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J. 1985 Aug;4(8):2009–2015. doi: 10.1002/j.1460-2075.1985.tb03885.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Roberts S., Bentley D. L. Distinct modes of transcription read through or terminate at the c-myc attenuator. EMBO J. 1992 Mar;11(3):1085–1093. doi: 10.1002/j.1460-2075.1992.tb05147.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Siebenlist U., Bressler P., Kelly K. Two distinct mechanisms of transcriptional control operate on c-myc during differentiation of HL60 cells. Mol Cell Biol. 1988 Feb;8(2):867–874. doi: 10.1128/mcb.8.2.867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Slungaard A., Confer D. L., Schubach W. H. Rapid transcriptional down-regulation of c-myc expression during cyclic adenosine monophosphate-promoted differentiation of leukemic cells. J Clin Invest. 1987 May;79(5):1542–1547. doi: 10.1172/JCI112987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Spencer C. A., Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res. 1991;56:1–48. doi: 10.1016/s0065-230x(08)60476-5. [DOI] [PubMed] [Google Scholar]
  35. Takimoto M., Quinn J. P., Farina A. R., Staudt L. M., Levens D. fos/jun and octamer-binding protein interact with a common site in a negative element of the human c-myc gene. J Biol Chem. 1989 May 25;264(15):8992–8999. [PubMed] [Google Scholar]
  36. Thompson C. B., Challoner P. B., Neiman P. E., Groudine M. Levels of c-myc oncogene mRNA are invariant throughout the cell cycle. 1985 Mar 28-Apr 3Nature. 314(6009):363–366. doi: 10.1038/314363a0. [DOI] [PubMed] [Google Scholar]
  37. Trepel J. B., Colamonici O. R., Kelly K., Schwab G., Watt R. A., Sausville E. A., Jaffe E. S., Neckers L. M. Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells. Mol Cell Biol. 1987 Jul;7(7):2644–2648. doi: 10.1128/mcb.7.7.2644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wagner A. J., Small M. B., Hay N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol. 1993 Apr;13(4):2432–2440. doi: 10.1128/mcb.13.4.2432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Wright S., Mirels L. F., Calayag M. C., Bishop J. M. Premature termination of transcription from the P1 promoter of the mouse c-myc gene. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11383–11387. doi: 10.1073/pnas.88.24.11383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Yuh Y. S., Thompson E. B. Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemic cell line CCRF-CEM. Specific c-myc mRNA suppression by dexamethasone. J Biol Chem. 1989 Jun 25;264(18):10904–10910. [PubMed] [Google Scholar]
  41. Zinn K., DiMaio D., Maniatis T. Identification of two distinct regulatory regions adjacent to the human beta-interferon gene. Cell. 1983 Oct;34(3):865–879. doi: 10.1016/0092-8674(83)90544-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES